Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-04-13Clinical Trial Update: Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP) [Phase 1, Phase 2]
This phase 1/2 trial evaluated carfilzomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma and has complet…
-
CLINICAL_TRIALS trial_result · 2016-04-11Clinical Trial Update: Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy [Phase 1, Phase 2]
A Phase 1/2 trial of delanzomib (CEP-18770) in relapsed/refractory multiple myeloma has been terminated before completion.
-
CLINICAL_TRIALS withdrawal · 2016-04-07Clinical Trial Update: UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib [Phase 2]
A Phase II open-label study evaluating the overall response rate of trametinib in multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2016-04-06Clinical Trial Update: Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM) [Phase 1, Phase 2]
This document reports the completion of a Phase 1/2 study evaluating Vorinostat in combination with Bortezomib, Doxorubicin, and Dexamethaso…
-
CLINICAL_TRIALS trial_result · 2016-04-04Clinical Trial Update: Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant [NA]
An exploratory trial evaluating the immune response to early PCV13 vaccination (Prevnar 13) given with autologous stem cell transplant in mu…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2016-04-01New treatment for patients with multiple myeloma
EMA announces a new treatment option for patients with multiple myeloma, indicating a new drug has been authorized or recommended for use in…
-
FDA approval · 2016-03-25FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Sagent Pharmaceuticals)
FDA approved a supplemental application for zoledronic acid filed by Sagent Pharmaceuticals.
-
CLINICAL_TRIALS trial_result · 2016-03-25Clinical Trial Update: Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma [Phase 2]
Phase 2 randomized trial in second-line multiple myeloma comparing lenalidomide with low-dose dexamethasone to lenalidomide alone; the study…
-
CLINICAL_TRIALS trial_result · 2016-03-25Clinical Trial Update: Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line
This is a completed non-interventional study assessing time to response and quality of life in relapsed/refractory multiple myeloma patients…
-
CLINICAL_TRIALS trial_result · 2016-03-24Clinical Trial Update: Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma [Phase 2]
Phase 2 clinical trial evaluating IPH2101, a human monoclonal antibody, for activity, safety and pharmacology in patients with multiple myel…
-
CLINICAL_TRIALS trial_result · 2016-03-17Clinical Trial Update: Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) [Phase 2]
A Phase 2 study evaluating donor lymphocyte infusion after allogeneic stem cell transplantation in leukemia and lymphoma was terminated, wit…
-
CLINICAL_TRIALS trial_result · 2016-03-16Clinical Trial Update: Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma [Phase 1]
This Phase 1 trial evaluates the CXCR4 antagonist BMS-936564 alone and in combination with lenalidomide/dexamethasone or bortezomib/dexameth…
-
CLINICAL_TRIALS trial_result · 2016-03-15Clinical Trial Update: Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma [Phase 1, Phase 2]
Clinical trial updates on adjuvant bortezomib maintenance after autologous stem cell transplantation in intermediate/advanced multiple myelo…
-
CLINICAL_TRIALS trial_result · 2016-03-11Clinical Trial Update: 1068GCC Evaluate Efficacy & Explore Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma [NA]
Clinical trial investigating acupuncture for bortezomib-induced peripheral neuropathy in multiple myeloma has completed with results posted.
-
FDA approval · 2016-03-10FDA Approved: EVOMELA — Original Application (Acrotech Biopharma Inc)
FDA approved EVOMELA (melphalan liposome injection) from Acrotech Biopharma as the original application, providing the first approval of thi…
-
CLINICAL_TRIALS research · 2016-03-10Clinical Trial Update: Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
This document provides an update on an ongoing Phase 1/2 clinical trial evaluating pomalidomide, dexamethasone, and pegylated liposomal doxo…
-
CLINICAL_TRIALS trial_result · 2016-03-03Clinical Trial Update: Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors [Phase 2]
Phase 2 results from a trial of peripheral blood stem cell transplantation using haploidentical related donors were completed, led by the Un…
-
CLINICAL_TRIALS research · 2016-02-29Clinical Trial Update: Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
Update on a clinical trial evaluating umbilical cord blood stem cell transplant for leukemia, lymphoma, and other hematologic conditions. Th…
-
CLINICAL_TRIALS trial_result · 2016-02-26Clinical Trial Update: Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma [Phase 2]
Phase 2 safety study of elotuzumab in combination with thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma has comp…
-
CLINICAL_TRIALS trial_result · 2016-02-26Clinical Trial Update: Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence [Phase 2]
Phase 2 study evaluating FluGlucoScan (F-fluorodeoxyglucose) in patients with known or suspected cancers; the trial status is completed.
-
CLINICAL_TRIALS trial_result · 2016-02-26Clinical Trial Update: Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating safety and efficacy of POL6326 for mobilization and transplant in hematologic malignancies has completed…
-
CLINICAL_TRIALS trial_result · 2016-02-26Clinical Trial Update: Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer [Phase 2]
Phase 2 trial update of Basiliximab to prevent graft-versus-host disease after nonmyeloablative allogeneic transplantation in blood cancers;…
-
CLINICAL_TRIALS trial_result · 2016-02-26Clinical Trial Update: Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT) [Phase 1, Phase 2]
A Phase 1/Phase 2 trial by UMC Utrecht evaluating lenalidomide, cyclophosphamide, and prednisone in multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2016-02-25Clinical Trial Update: Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma [Phase 3]
A Phase 3 randomized trial comparing Rd (lenalidomide + low-dose dexamethasone) versus VRd (bortezomib + lenalidomide + low-dose dexamethaso…
-
CLINICAL_TRIALS trial_result · 2016-02-22Clinical Trial Update: Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy [Phase 2]
Phase 2 study evaluating Tecemotide (L-BLP25) in slowly progressive, asymptomatic multiple myeloma patients who had no prior chemotherapy; t…